Blog
This post contains excerpts from the June 2019 cover article in PharmaVOICE Magazine, written by Robin Robinson. Cognizant has been using AR technology at clinical congresses for several years, says Bryan Hill, chief technology officer, life sciences, Cognizant. One particul … Read More »
In the June Speak OUT feature in PharmaVOICE Magazine, Larissa Comis of Cognizant describes how the Cognizant Shared Investigator Platform is a disruptive innovation that can help companies achieve positive outcomes. Best Practices for Adopting the Shared Investigator Platfo … Read More »
CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health(signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signan … Read More »
In a June 6 webinar, industry experts from Inteliquet will demonstrate specifically how machine learning can augment and assist human intelligence to perform better patient forecasting. By extracting pertinent EMR information, including physicians’ notes, reading binary dat … Read More »
If there are lingering doubts about the viability or market potential of digital therapeutics (DTx), recent moves by the U.S. Food & Drug Administration should lay them to rest. In December 2018, Pear Therapeutics and its partner, Novartis’ Sandoz unit, received FDA clea … Read More »
Listening and interpreting the patient’s views throughout their journey of care is an important and elusive goal. inVibe Labs has developed a lexicon guide for disease states, that helps shed some light on what a patient is saying about their care as they progress through th … Read More »
The importance of a good agency/client relationship cannot be overstated. In the May issue of PharmaVOICE magazine, Allison Davis of closerlook provides insights and advice into making this crucial relationship work. Read article http://bit.ly/PV-May2019-56 Here are some of … Read More »
Evidera has published an informative article to provide some baseline knowledge about the “why, who, what, and how” when it comes to clinical outcome assessments for rare disease trials. Read the article: http://bit.ly/Evidera05202019 Key points in the paper: Patient inclus … Read More »
An upcoming webinar explores Service Design Methods as a way of accelerating business objectives and improving the patient experience. Industry experts will share their knowledge and experiences on this topic, and will field questions from the audience after their presentati … Read More »
In a June 6 webinar, industry experts from Inteliquet will demonstrate specifically how machine learning can augment and assist human intelligence to perform better patient forecasting. By extracting pertinent EMR information, including physicians’ notes, reading binary dat … Read More »
Evidera has released a white paper related to the January FDA revised draft guidance on rare and orphan drug development. The use of social media is recommended to help make the drug development process more efficient. This includes identifying rare disease patients for clin … Read More »
Read full article http://bit.ly/PVEx0419 There are currently 350 million people worldwide suffering from rare diseases, and half of them are children. Parents are the strongest advocates for their children suffering with rare diseases, pushing researchers, companies and regu … Read More »
Submitted by: Linda Ross, MPH, Senior Director, Peri- and Post-Approval Operations, Evidera Advancements in gene therapy and transformative medicine have had a major impact on the development of treatments for rare diseases, resulting in a growing need for evidence of the s … Read More »
Provided by Evidera The increasing development of orphan drugs and precision medicine has led to novel needs in terms of real-world evidence generation. A key area recently highlighted in the FDA’s updated draft guidance on rare diseases is the recommendation of natural hist … Read More »
Provided by INmune Bio Primary and secondary resistance to therapy is a defining characteristic of progressive cancer in man. Patients and their clinical teams repeat the cycle of treatment, remission, relapse and retreatment until an effective therapy is found or the patien … Read More »
Contributed by: Matt Giegerich, CEO and Shaun Urban, President, The Inception Company Read the full article. https://www.pharmavoice.com/digital-edition/march-2019/#11 When two veteran healthcare advertising executives decide to rejoin forces, the natural — and expected — as … Read More »
Executives reflect on the major shifts in the industry in the last 15 years and the evolving market dynamics that will impact global communication. Watch the video now http://bit.ly/InceptionMar2019 Key points: Technology, digital, and data are driving change. The compressio … Read More »
Contributed by: Srini Shankar, Vice President, Life Sciences, Cognizant Read full article http://bit.ly/0219-RedZone It is not the strongest of the species that survives, nor is it the most intelligent. It is the one that is most adaptable to change. Whether a direct quote f … Read More »
See the results of a Forrester study on digital transformation http://bit.ly/0219-Executive Winning in today’s digital era requires more than just apps and a website. Fusing an enterprise for success in the digital era requires companies to seamlessly collaborate across the … Read More »
75% of Americans seek medical information online at least once a month—and yet, just 11% of clinical trials implement social-media efforts to recruit participants. Perhaps consequently, nearly half of all clinical trials fail to meet their target enrollment numbers. There is … Read More »
